101
|
Wang F, Xing T, Li J, Bai M, Hu R, Zhao Z, Tian S, Zhang Z, Wang N. Renalase's expression and distribution in renal tissue and cells. PLoS One 2012; 7:e46442. [PMID: 23056310 PMCID: PMC3463591 DOI: 10.1371/journal.pone.0046442] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2012] [Accepted: 08/30/2012] [Indexed: 12/19/2022] Open
Abstract
To study renalase's expression and distribution in renal tissues and cells, renalase coded DNA vaccine was constructed, and anti-renalase monoclonal antibodies were produced using DNA immunization and hybridoma technique, followed by further investigation with immunological testing and western blotting to detect the expression and distribution of renalase among the renal tissue and cells. Anti-renalase monoclonal antibodies were successfully prepared by using DNA immunization technique. Further studies with anti-renalase monoclonal antibody showed that renalase expressed in glomeruli, tubule, mesangial cells, podocytes, renal tubule epithelial cells and its cells supernatant. Renalase is wildly expressed in kidney, including glomeruli, tubule, mesangial cells, podocytes and tubule epithelial cells, and may be secreted by tubule epithelial cells primarily.
Collapse
Affiliation(s)
- Feng Wang
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
- * E-mail: (FW); (NW)
| | - Tao Xing
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Australia
| | - Junhui Li
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
| | - Mei Bai
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
| | - Ruimin Hu
- Department of Pathology, Shanghai Medical College, Fudan Univesity, Shanghai, China
| | - Zhonghua Zhao
- Department of Pathology, Shanghai Medical College, Fudan Univesity, Shanghai, China
| | - Shoufu Tian
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
| | - Zhigang Zhang
- Department of Pathology, Shanghai Medical College, Fudan Univesity, Shanghai, China
| | - Niansong Wang
- Department of Nephrology and Rheumatology, Shanghai Sixth People's Hospital affiliated to Shanghai Jiaotong University, Shanghai, China
- * E-mail: (FW); (NW)
| |
Collapse
|
102
|
Wang F, Zhao Q, Xing T, Li J, Wang N. Renalase-Specific Polyclonal Antibody and Its Application in the Detection of Renalase's Expression. Hybridoma (Larchmt) 2012; 31:378-81. [PMID: 23098306 DOI: 10.1089/hyb.2012.0026] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Feng Wang
- Department of Nephrology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Qing Zhao
- Department of Cardiology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Tao Xing
- Florey Neuroscience Institute, University of Melbourne, Parkville, Victoria, Australia
| | - Junhui Li
- Department of Nephrology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
| | - Niansong Wang
- Department of Nephrology, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China
| |
Collapse
|
103
|
Malyszko J, Malyszko JS, Rysz J, Mysliwiec M, Tesar V, Levin-Iaina N, Banach M. Renalase, hypertension, and kidney - the discussion continues. Angiology 2012; 64:181-7. [PMID: 22969162 DOI: 10.1177/0003319712459212] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Hypertension and cardiovascular complications are very common in chronic kidney disease (CKD). Overactivation of sympathetic nervous system is also widely recognized in CKD. Renalase may play an important role in the control of blood pressure (BP) by its regulatory function of catecholamine metabolism. Renalase could be synthesized not only by the kidney but also by cardiomyocytes, liver, and adipose tissue. It probably exerts a hypotensive action, at least in animal models. Whether it metabolizes catecholamines remains to be proved. Another issue that remains to be resolved is the relationship between renalase and renal natriuresis and phosphaturia. In this review, the updated experimental and clinical data on renalase are presented and possible interactions with the endothelium are discussed. Renalase is "a new postulated therapeutic target." Proof of concept studies are needed to define the pathophysiological link between the kidney, sympathetic tone, BP, and cardiovascular complications.
Collapse
Affiliation(s)
- Jolanta Malyszko
- Department of Nephrology and Transplantology, Medical University in Bialystok, Bialystok, Poland.
| | | | | | | | | | | | | |
Collapse
|
104
|
Desir GV, Tang L, Wang P, Li G, Sampaio-Maia B, Quelhas-Santos J, Pestana M, Velazquez H. Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline. J Am Heart Assoc 2012; 1:e002634. [PMID: 23130169 PMCID: PMC3487338 DOI: 10.1161/jaha.112.002634] [Citation(s) in RCA: 82] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2012] [Accepted: 05/18/2012] [Indexed: 01/11/2023]
Abstract
BACKGROUND Blood pressure is acutely regulated by the sympathetic nervous system through the action of vasoactive hormones such as epinephrine, norepinephrine, and dopamine. Renalase, a recently described, secreted flavoprotein, acutely decreases systemic pressure when administered in vivo. Single-nucleotide polymorphisms present in the gene are associated with hypertension, cardiac disease, and diabetes. Although renalase's crystal structure was recently solved, its natural substrate(s) remains undefined. METHODS AND RESULTS Using in vitro enzymatic assays and in vivo administration of recombinant renalase, we show that the protein functions as a flavin adenine dinucleotide- and nicotinamide adenine dinucleotide-dependent oxidase that lowers blood pressure by degrading plasma epinephrine. The enzyme also metabolizes the dopamine precursor l-3,4-dihydroxyphenylalanine but has low activity against dopamine and does not metabolize norepinephrine. To test if epinephrine and l-3,4-dihydroxyphenylalanine were renalase's only substrates, 17 246 unique small molecules were screened. Although the search revealed no additional, naturally occurring compounds, it identified dobutamine, isoproterenol, and α-methyldopa as substrates of renalase. Mutational analysis was used to test if renalase's hypotensive effect correlated with its enzymatic activity. Single-amino acid mutations that decrease its enzymatic activity to varying degrees comparably reduce its hypotensive effect. CONCLUSIONS Renalase metabolizes circulating epinephrine and l-3,4-dihydroxyphenylalanine, and its capacity to decrease blood pressure is directly correlated to its enzymatic activity. These findings highlight a previously unrecognized mechanism for epinephrine metabolism and blood pressure regulation, expand our understanding of the sympathetic nervous system, and could lead to the development of novel therapeutic modalities for the treatment of hypertension. (J Am Heart Assoc. 2012;1:e002634 doi: 10.1161/JAHA.112.002634.).
Collapse
Affiliation(s)
- Gary V Desir
- Yale University School of Medicine, Department of Medicine, New Haven, CT (G.V.D., L.Q.T., P.W., G.L., H.V.) ; VA Connecticut Healthcare System (VACHS) Medical Center, West Haven, CT (G.V.D., L.Q.T., P.W., G.L., H.V.)
| | | | | | | | | | | | | | | |
Collapse
|
105
|
The Renalase Asp37Glu polymorphism is not associated with hypertension and cardiovascular events in an urban-based prospective cohort: the Malmö Diet and cancer study. BMC MEDICAL GENETICS 2012; 13:57. [PMID: 22812913 PMCID: PMC3458972 DOI: 10.1186/1471-2350-13-57] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/07/2012] [Accepted: 07/10/2012] [Indexed: 01/11/2023]
Abstract
Background Renalase (gene name RNLS), a recently discovered enzyme with monoamine oxidase activity, is implicated in the degradation of catecholamines. Recent studies delineate a possible role of this enzyme in blood pressure (BP) maintenance and cardiac protection and two single nucleotide polymorphisms, RNLS rs2576178 A > G and rs2296545 C > G have been associated with hypertension. The latter SNP leads to a non synonymous Asp to Glu substitution deleting a flavin adenine dinucleotide (FAD) binding site with possible impaired functionality. We tested the hypothesis that these polymorphisms could affect BP levels, hypertension prevalence, and risk of incident cardiovascular events in middle-aged Swedes. Methods The polymorphisms were genotyped in 5696 participants of the population-based Cardiovascular Cohort of the "Malmö Diet and Cancer" (MDC-CC). The incidence of cardiovascular events (coronary events [n = 408], strokes [n = 330], heart failure [n = 190] and atrial fibrillation/flutter [n = 406]) was monitored for an average of approximately 15 years of follow-up. Results Both before and after adjustment for sex, age and BMI the polymorphisms did not show any effect on BP level and hypertension prevalence. Before and after adjustment for major cardiovascular risk factors, the hazard ratio for cardiac and cerebrovascular events was not significantly different in carriers of different genotypes. A significant interaction was found between the rs2296545 C > G and age with respect to BP/hypertension. Conclusions Our data do not support a major role for these RNLS polymorphisms in determining BP level and incident events at population level. The positive interaction with age suggest that the effect of the rs2296545 C > G polymorphism, if any, could vary between different ages.
Collapse
|
106
|
Malyszko J, Koc-Zorawska E, Malyszko JS, Kozminski P, Zbroch E, Mysliwiec M. Renalase, Stroke, and Hypertension in Hemodialyzed Patients. Ren Fail 2012; 34:727-31. [DOI: 10.3109/0886022x.2012.681534] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
|
107
|
|
108
|
Przybylowski P, Malyszko J, Kozlowska S, Malyszko J, Koc-Zorawska E, Mysliwiec M. Serum Renalase Depends on Kidney Function But Not on Blood Pressure in Heart Transplant Recipients. Transplant Proc 2011; 43:3888-91. [DOI: 10.1016/j.transproceed.2011.08.075] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2011] [Accepted: 08/29/2011] [Indexed: 11/29/2022]
|
109
|
Buraczynska M, Zukowski P, Buraczynska K, Mozul S, Ksiazek A. Renalase gene polymorphisms in patients with type 2 diabetes, hypertension and stroke. Neuromolecular Med 2011; 13:321-7. [PMID: 21964580 PMCID: PMC3220827 DOI: 10.1007/s12017-011-8158-6] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2011] [Accepted: 09/14/2011] [Indexed: 01/09/2023]
Abstract
Renalase is a novel, recently identified, flavin adenine dinucleotide-dependent amine oxidase. It is secreted by the kidney and metabolizes circulating catecholamines. Renalase has significant hemodynamic effects, therefore it is likely to participate in the regulation of cardiovascular function.The aim of our study was to investigate the involvement of renalase gene polymorphisms in hypertension in type 2 diabetes patients. A total of 892 patients and 400 controls were genotyped with three SNPs in the renalase gene. The C allele of rs2296545 SNP was associated with hypertension (P < 0.01). For rs2576178 SNP, frequencies in hypertensive patients differed from controls, but not from normotensive patients. For rs10887800 SNP, the differences in the G allele frequencies were observed in hypertensive patients with stroke, with 66% of patients being GG homozygotes. To confirm observed association we later genotyped 130 stroke patients without diabetes. The OR for risk allele was 1.79 (95% CI 1.33-2.41). In conclusion, the renalase gene polymorphism was associated with hypertension in type 2 diabetes patients. The most interesting result is a strong association of the rs10887800 polymorphism with stroke in patients with and without diabetes. The G allele of this polymorphism might thus be useful in identifying diabetes patients at increased risk of stroke.
Collapse
Affiliation(s)
- Monika Buraczynska
- Laboratory for DNA Analysis and Molecular Diagnostics, Department of Nephrology, Medical University of Lublin, Dr K. Jaczewskiego 8, 20-954, Lublin, Poland.
| | | | | | | | | |
Collapse
|
110
|
Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J 2011; 32:2739-47. [PMID: 21951628 PMCID: PMC3214724 DOI: 10.1093/eurheartj/ehr253] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The conventional antihypertensive therapies including renin–angiotensin–aldosterone system antagonists (converting enzyme inhibitors, receptor blockers, renin inhibitors, and mineralocorticoid receptor blockers), diuretics, β-blockers, and calcium channel blockers are variably successful in achieving the challenging target blood pressure values in hypertensive patients. Difficult to treat hypertension is still a commonly observed problem world-wide. A number of drugs are considered to be used as novel therapies for hypertension. Renalase supplementation, vasopeptidase inhibitors, endothelin antagonists, and especially aldosterone antagonists (aldosterone synthase inhibitors and novel selective mineralocorticoid receptor blockers) are considered an option in resistant hypertension. In addition, the aldosterone antagonists as well as (pro)renin receptor blockers or AT2 receptor agonists might attenuate end-organ damage. This array of medications has now been complemented by a number of new approaches of non-pharmacological strategies including vaccination, genomic interference, controlled breathing, baroreflex activation, and probably most successfully renal denervation techniques. However, the progress on innovative therapies seems to be slow and the problem of resistant hypertension and proper blood pressure control appears to be still persisting. Therefore the regimens of currently available drugs are being fine-tuned, resulting in the establishment of several novel fixed-dose combinations including triple combinations with the aim to facilitate proper blood pressure control. It remains an exciting question which approach will confer the best blood pressure control and risk reduction in this tricky disease.
Collapse
Affiliation(s)
- Thomas Unger
- Center for Cardiovascular Research, Charité-University Medicine, Hessische Str 3-4, Berlin 10115, Germany.
| | | | | |
Collapse
|
111
|
FAD-binding site and NADP reactivity in human renalase: a new enzyme involved in blood pressure regulation. J Mol Biol 2011; 411:463-73. [PMID: 21699903 DOI: 10.1016/j.jmb.2011.06.010] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2011] [Revised: 06/06/2011] [Accepted: 06/07/2011] [Indexed: 01/05/2023]
Abstract
Renalase is a recently discovered flavoprotein that regulates blood pressure, regulates sodium and phosphate excretion, and displays cardioprotectant action through a mechanism that is barely understood to date. It has been proposed to act as a catecholamine-degrading enzyme, via either O(2)-dependent or NADH-dependent mechanisms. Here we report the renalase crystal structure at 2.5 Å resolution together with new data on its interaction with nicotinamide dinucleotides. Renalase adopts the p-hydroxybenzoate hydroxylase fold topology, comprising a Rossmann-fold-based flavin adenine dinucleotide (FAD)-binding domain and a putative substrate-binding domain, the latter of which contains a five-stranded anti-parallel β-sheet. A large cavity (228 Å(3)), facing the flavin ring, presumably represents the active site. Compared to monoamine oxidase or polyamine oxidase, the renalase active site is fully solvent exposed and lacks an 'aromatic cage' for binding the substrate amino group. Renalase has an extremely low diaphorase activity, displaying lower k(cat) but higher k(cat)/K(m) for NADH compared to NADPH. Moreover, its FAD prosthetic group becomes slowly reduced when it is incubated with NADPH under anaerobiosis, and binds NAD(+) or NADP(+) with K(d) values of ca 2 mM. The absence of a recognizable NADP-binding site in the protein structure and its poor affinity for, and poor reactivity towards, NADH and NADPH suggest that these are not physiological ligands of renalase. Although our study does not answer the question on the catalytic activity of renalase, it provides a firm framework for testing hypotheses on the molecular mechanism of its action.
Collapse
|
112
|
|
113
|
|